Rhythm Pharmaceuticals, Inc.
Clinical trials sponsored by Rhythm Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing therapies for rare genetic obesity disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Gene-Targeted obesity drug shows promise in phase 3 trial
Disease control CompletedThis phase 3 trial is testing a drug called setmelanotide in people with obesity linked to certain gene variants (POMC, PCSK1, LEPR, NCOA1, or SH2B1). About 296 participants, aged 6 to 65, will receive either the drug or a placebo to see if it helps reduce body weight. The study …
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Hope for rare obesity: setmelanotide tested for long-term safety
Disease control CompletedThis study looks at the long-term safety of setmelanotide (Imcivree) in 30 people aged 2 and older with rare genetic obesity. Participants have already completed a previous setmelanotide study and shown benefit. They will receive daily injections to see if the drug remains safe a…
Phase: PHASE3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New pill targets hard-to-treat obesity after brain injury
Disease control CompletedThis study tested an experimental daily pill, LB54640, in 28 people aged 12 and older with hypothalamic obesity—a condition where brain injury causes rapid, severe weight gain. For the first 14 weeks, some received the drug and some a placebo to see if it safely reduces weight an…
Phase: PHASE2 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC